The fully automated test utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting faster and better-informed treatment and patient management decisions, DiaSorin said.

The test also drives laboratory operational efficiency through time-labor reduction by using a fully automated and high-throughput approach when compared with traditional growth-based microbiology methods, the firm added.

The company said it is launching the blood-based assay in the U.S. and noted that the launch follows a licensing agreement inked with MeMed in September 2020.

Under the agreement, DiaSorin obtained the rights to commercialize and make the MeMed BV test available on its large installed base of Liaison platforms.

The test provides a valuable tool in the growing global threat posed by antimicrobial resistance, DiaSorin said.

The firm announced the clearance ahead of AACC 2022 in Chicago.

BrightInsight launches digital diagnostics platform at AACC
BrightInsight on Monday announced the launch of its digital Connected Diagnostics Platform at the 2022 AACC Annual Scientific Meeting and Clinical Lab...

LumiraDx to discuss microfluidic technology at AACC
LumiraDx announced that it will host an industry workshop at AACC 2022 on Wednesday, describing the impact of its microfluidic technology on lateral-flow...

Cytovale to present new data on rapid sepsis test at AACC
Cytovale said Monday that it will present new data at AACC 2022 about its 10-minute IntelliSep test for sepsis and its associated system.

Companies announce new products ahead of AACC 2022
Several companies have announced the launch of laboratory diagnostic products in advance of AACC 2022.

Survey finds low morale among lab professionals
Lighthouse Lab Services on Wednesday announced the results of its first wage and morale survey of medical laboratory professionals, saying that despite...

Beckman, Scopio to partner on blood smear platforms
Beckman Coulter Diagnostics on Wednesday announced that it has partnered with Scopio Labs to accelerate adoption of Scopio's next-generation peripheral...

AACC sees rise in impact of medical laboratory journal
AACC recently announced that the impact factor of its journal Clinical Chemistry has risen to 12.167 in the 2021 Clarivate Journal Citation Reports.